Published in Cell on April 28, 2016
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol (2017) 0.81
The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75
Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. Cell Discov (2017) 0.75
Human Vaccines & Immunotherapeutics: News. Hum Vaccin Immunother (2016) 0.75
Gynaecological cancer: Chemoresistance - a little help from friends. Nat Rev Clin Oncol (2016) 0.75
Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior. Dis Model Mech (2016) 0.75
Microenvironmental InterFereNce of metabolism regulates chemosensitivity. Cell Res (2016) 0.75
Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol (2017) 0.75
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol (2017) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell (2014) 5.87
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41
CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell (2011) 3.41
Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest (2006) 2.64
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol (2012) 2.59
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem (1993) 2.12
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids (2012) 1.77
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity (2013) 1.77
Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. Proc Natl Acad Sci U S A (1989) 1.66
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 1.56
Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs (2010) 1.25
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol (2015) 1.14
Functional relevance of the histone gammaH2Ax in the response to DNA damaging agents. Proc Natl Acad Sci U S A (2011) 1.12
MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer. Hum Mutat (2010) 1.01
Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol (2000) 0.91
Kinetic study of the reaction of cisplatin with thiols. Drug Metab Dispos (2002) 0.89
Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends Mol Med (2015) 0.84
IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity (2014) 2.08
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med (2016) 0.95
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget (2016) 0.77
Dendritic cells are stressed out in tumor. Cell Res (2015) 0.75